ArticleXenotransplantation2017
Anti-CD40 antibody-mediated costimulation blockade promotes long-term survival of deep-lamellar porcine corneal grafts in non-human primates.
Article in Xenotransplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- A Comparative Analysis of Pig-to-Rhesus Corneal Xenotransplantation with Various Immunosuppressive Regimens.Korean journal of ophthalmology : KJO · 2026Article
- Article
- The immunobiology and clinical use of genetically engineered porcine hearts for cardiac xenotransplantation.Nature cardiovascular research · 2022Article
- The first clinical pig heart transplant: Was IVIg or pig cytomegalovirus detrimental to the outcome?Xenotransplantation · 2022Review
- An optional surgical technique for obtaining lamellar donor grafts: a pilot study.BMC ophthalmology · 2022Article
- Genetic engineering of pigs for xenotransplantation to overcome immune rejection and physiological incompatibilities: The first clinical steps.Frontiers in immunology · 2022Review
- Corneal xenotransplantation: Where are we standing?Progress in retinal and eye research · 2021Review
- Anti-CD40 antibody 2C10 binds to a conformational epitope at the CD40-CD154 interface that is conserved among primate species.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020Article
- Predictive biomarkers for graft rejection in pig-to-non-human primate corneal xenotransplantation.Xenotransplantation · 2019Article
- Genetically-engineered pigs as sources for clinical red blood cell transfusion: What pathobiological barriers need to be overcome?Blood reviews · 2019Review
- Cardiac xenografts show reduced survival in the absence of transgenic human thrombomodulin expression in donor pigs.Xenotransplantation · 2019Article
- Reducing porcine corneal graft rejection, with an emphasis on porcine endogenous retrovirus transmission safety: a review.International journal of ophthalmology · 2019Review
- Reduction of the survival time of pig xenotransplants by porcine cytomegalovirus.Virology journal · 2018Review
- Long-term safety outcome of systemic immunosuppression in pig-to-nonhuman primate corneal xenotransplantation.Xenotransplantation · 2018Article
- Xenotransplantation: past, present, and future.Current opinion in organ transplantation · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundCorneal xenotransplantation is an effective solution for the shortage of human donor corneas, and the porcine cornea may be a suitable candidate for the donor cornea because of its optical similarity with humans. However, it is necessary to administer additional immunosuppressants to overcome antigenic differences. We aimed to investigate the feasibility of porcine corneas with anti-CD40 antibody-mediated costimulation blockade in a clinically applicable pig-to-non-human primate corneal xenotransplantation model.
methodsFive Chinese rhesus macaques underwent deep-lamellar corneal transplantation using clinically acceptable sized (7.5 mm diameter) porcine corneal grafts. The anti-CD40 antibody was intravenously administered on a programmed schedule. Graft survival, central corneal thickness, and intraocular pressure were evaluated. Changes in effector and memory T and B cell subsets and anti-αGal and donor-specific antibodies were investigated in the blood, and the changes in complement levels in the aqueous humor and blood were evaluated. Memory cell profiles in the anti-CD40 antibody-treated group were compared with those from the anti-CD154 antibody-treated group or rejected controls presented in our previous report. The changes in anti-αGal, non-αGal, and donor-specific antibodies after 6 months were compared with baseline values.
resultsAnti-CD40 antibody-mediated costimulation blockade resulted in the successful survival of xenocorneal grafts (>389, >382, >236, >201, and >61 days), with 80% reaching 6 months of survival. Injection of anti-CD40 antibody considerably reduced the infiltration of inflammatory cells into the grafts and significantly blocked the complement response in the aqueous humor (P=.0159, Mann-Whitney U test). Systemic expansion of central or effector memory T cells was abrogated in the anti-CD40 antibody-treated primates compared with those in the rejected controls (P<.05, Mann-Whitney U test) or those in the anti-CD154 antibody-treated primates (P>.05, Mann-Whitney U test). The levels of anti-αGal, non-αGal, and donor-specific antibodies at 6 months were not significantly increased compared with baseline levels (P>.05, Wilcoxon signed rank test).
conclusionsAn anti-CD40 antibody-mediated blockade appears to be effective immunosuppressive approach for porcine corneal deep-lamellar xenotransplantation in primates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.